NAICONS

WHO WE ARE

Naicons is dedicated to the discovery and characterization of bioactive compounds, in particular novel classes of antibiotics. Our own programs aim at combating and preventing a broad range of infectious diseases. Our research collaborations offer access to our technology platform and expertise to solve a client's need, like identifying drug leads, optimizing production processes, preparing a master cell bank, etc.

GET IN TOUCH

Naicons Laboratories
Fondazione UniMI
Viale Ortles 22/4
20139 Milan, Italy

www.naicons.com

NAICONS

NATURAL PRODUCTS DISCOVERY

NAICONS' PLATFORM

Naicons' platform consists of a large and diversified strain library, the products those microbes provide, a database connecting different type of informations and our team's deep expertise. The platform has broad applicability across a diverse number of therapeutic areas and opens the way to new and innovative collaborations.

ASSETS

Naicons' asset libraries are some of the largest and most diversified in the world. These collections drive the discovery of new drugs that address unmet medical needs and have broad applicability across a diverse number of therapeutic areas.

MICROBIAL STRAIN LIBRARY

A collection of about **45,000 actinomycetes** isolated from different sources using proprietary methods. The collection includes strains from over 60 different genera, including strains belonging to unusual and hard-to-isolate genera rarely found in public strain collections. Many strains have associated genomic information. A historical collection of over 10,000 soil samples can provide a virtually endless source of additional strains.

MICROBIAL EXTRACT LIBRARY

Using proprietary cultivation methods devised to optimize production of bioactive metabolites, Naicons' strains are used to generate **a library of dried microbial extracts** in ready-to-screen, 96-well microplates. Different extraction procedures are applied to cultures, ensuring compatibility with most screening assays. We also produce pre-fractionated extracts.

METABOLITE FINGERPRINTS

All extracts are used to generate **MS-MS and UV-Vis fingerprints**, which are then combined through molecular networking to identify structurally-related metabolites within one extract and among different extracts. By comparison with our database of known microbial products, this approach rapidly identifies common known compounds, unusual known compounds, as well as plenty of novel molecules.

PURIFIED MICROBIAL PRODUCTS

Purified microbial products are also available. This collection includes undescribed compounds, molecules first reported by Naicons' team or rare metabolites.

OUTLICENSING OPPORTUNITIES FOR NAICONS ADVANCED COMPOUNDS

NAI-107

A family of related lantibiotics highly active against aerobic and anaerobic Gram-positive pathogens, including all antibiotic-resistant strains (e.g. MRSA and VRE); rapidly bactericidal and highly efficacious in experimental models of infection, with favorable PK/PD properties and toxicological profile. NAI-107 is being developed for iv treatment of serious infections by gram-positive bacteria.

NAI-603

A semi-synthetic derivative of ramoplanin highly active against aerobic and anareobic Gram-positive pathogens, including all antibiotic-resistant strains (e.g. MRSA and VRE); rapidly bactericidal, well-tolerated and efficacious in experimental models of infection. It can be developed for iv or topical use for several indications. Favorable toxicological profile.

NAI-112

A lanthipeptide with efficacy in animal models of nociceptic and inflammatory pain. Likely to act through the vanilloid pathway by a novel target. It can be developed for the treatment of neuropathic pain.

PUM (PSEUDOURIDIMYCIN)

A novel class of RNA polymerase inhibitors with extremely low frequency of resistance selection. Active against Gram-positive and Gram-negative pathogens,including antibiotic-resistant isolates, with efficacy in animal models of infection.

CONTACT US FOR MORE INFO